Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
human umbilical cord mesenchymal stem cells + human cord blood mononuclear cells (Beike Biotechnology)
- Development stage
- Unknown
- Lead developer
- Beike Biotechnology
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous, Intraparenchymal
01
Overview
This combination cell therapy consists of human umbilical cord mesenchymal stem cells (hUCMSCs) and human cord blood mononuclear cells (hCBMNCs), developed by Shenzhen Beike Bio-Technology. It is currently being evaluated in Phase 1/2 clinical trials for the treatment of premature ovarian failure (POF), typically administered in conjunction with hormone replacement therapy (HRT). hUCMSCs are multipotent stem cells known for their immunomodulatory, anti-inflammatory, and pro-angiogenic properties, which are thought to help repair damaged ovarian tissue and restore the follicular microenvironment. hCBMNCs provide a diverse population of hematopoietic and progenitor cells that may further support vascularization and tissue regeneration. The primary therapeutic goal is to restore ovarian function, normalize hormone levels (such as serum gonadotropins and estrogen), and potentially improve fertility in women under the age of 40 affected by POF.
- Other names
- hUCMSCs + hCBMNCshuman umbilical cord mesenchymal stem cells and human cord blood mononuclear cells
Beyond the preview
Go deeper on human umbilical cord mesenchymal stem cells + human cord blood mononuclear cells (Beike Biotechnology).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on human umbilical cord mesenchymal stem cells + human cord blood mononuclear cells (Beike Biotechnology).